ClinicalTrials.gg
Active, not recruitingNCT06329401Updated Nov 5, 2026

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

A Phase 2 interventional study of AP01 and Placebo in Pulmonary Fibrosis, Progressive Pulmonary Fibrosis and Pulmonary Fibrosis Secondary to Systemic Sclerosis, sponsored by Avalyn Pharma Inc.. Active, not recruiting at 154 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Avalyn Pharma Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Enrollment updatedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.

Enrollment
11th of 90
398 · median 50
Started
2024
with 3 others
Phase 2
43 of 128
9 open now
Primary completion
2027-06
later than 16 of 38 live
Registered
116th of 128
by date

Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 11th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2024, is one of 43 in phase 2, reaches primary completion later than 16 of the 38 other live ones, and was the 116th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.

Read the detailed description

This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 (pirfenidone solution for inhalation) versus placebo on top of standard of care in participants with PPF over 52 weeks. Up to 300 eligible participants will be randomized to 1 of 3 treatment arms: AP01 high dose, AP01 low dose, or placebo.

03

Conditions studied

  • Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
  • Pulmonary Fibrosis Secondary to Systemic Sclerosis
  • Pulmonary Fibrosis, Interstitial Lung Disease
  • Interstitial Lung Disease
  • Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
  • Interstitial Lung Disease in Patients With Rheumatoid Arthritis
  • Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere
  • Hypersensitivity Pneumonitis
  • Interstitial Lung Disease With Systemic Sclerosis

Keywords

  • Chronic-Fibrosing-ILD with progressive phenotype, PF-ILD
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant meets criteria for PPF, as follows:
  • In subjects with interstitial lung disease (ILD) of known or unknown etiology other than idiopathic pulmonary fibrosis (IPF) who have radiological evidence of pulmonary fibrosis, PPF is defined as:

Physiological evidence of disease progression with at least 1 of the following criteria despite treatment with approved or unapproved medications commonly used in practice (per Investigator):

  1. Relative decline in FVC ≥10% predicted within the previous 24 months based on documented historical spirometry assessments
  2. Relative decline in FVC ≥5% to \<10% predicted within the previous 24 months based on documented historical spirometry assessments with at least 1 of the 2 following criteria:

    • Worsening respiratory symptoms (Note: Changes attributable to comorbidities e.g., infection, heart failure must be excluded) OR
    • Radiological (HRCT) evidence of disease progression per a local or central radiologist (from historical HRCT taken up to 24 months prior to Screening Visit 1), for example:

      • Increased extent or severity of traction bronchiectasis and bronchiolectasis
      • New ground-glass opacity with traction bronchiectasis
      • New fine reticulation
      • Increased extent or increased coarseness of reticular abnormality
      • New or increased honeycombing
      • Increased lobar volume loss
  3. Worsening of respiratory symptoms (Note: Changes attributable to comorbidities e.g., infection, heart failure must be excluded) AND radiological (HRCT) evidence of disease progression per a local or central radiologist

    • Meeting all of the following criteria during the Screening Period:

a. FVC ≥45% of predicted normal at Screening Visit 1, b. Forced expiratory volume at 1 second ()/FVC ≥0.7 or ≥age-adjusted lower limit of normal at Screening Visit 1, c. Diffusing capacity of lung for carbon monoxide (DLCO) ≥30% of predicted, corrected for at Screening Visit 1, d. Acceptability: Participants can perform acceptable spirometry (i.e., meet American Thoracic Society (ATS)/ European Respiratory Society (ERS) acceptability criteria at both Screening Visits).

  • For subjects already on background therapy (nintedanib or nerandomilast 18 mg twice daily [up to 30% of subjects]): Must have been on background therapy for at least 12 weeks prior to Screening with or without dose adjustments and/or drug interruptions during that period. For subjects who have discontinued background therapy prior to Screening: Must have been off for a minimum of 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Current treatment with oral pirfenidone or nerandomilast 9 mg twice daily dose or treatment with oral pirfenidone within 3 months prior to Screening.
  • Elevated liver enzymes and liver injury at Screening defined as:

    1. (ALT) or aspartate aminotransferase (AST) ˃ 3 times the (ULN)
    2. >2.0 x ULN
  • Renal disease with a \< 30 mL/min, calculated according to the Chronic Kidney Disease Epidemiology Collaboration formula. Retesting is allowed once.
  • Diagnosis of idiopathic pulmonary fibrosis (IPF) based on the ATS diagnostic algorithm for IPF. UIP that is not idiopathic, for example related to rheumatoid arthritis (RA), familial interstitial lung disease (ILD), or other is not exclusionary.
  • Greater extent of emphysema than of fibrotic ILD on HRCT. Note: CT results must be confirmed through the central over read process.
  • Significant clinical worsening of PPF between Screening Visit 1 and Visit 3
  • Participants who cannot meet protocol-specified Baseline stability criteria. FVC Baseline stability is defined as the FVC assessments at Visit 3 being within ±12% of the mean of the FVC assessments obtained at the 2 preceding visits. At Visit 3, if the pre-dose FVC is outside of ±12% range, the participant will not be randomized and will be considered a screen failure.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
398 participants (actual)

Study arms

  • Experimental
    AP01 High Dose BID

    Pirfenidone Solution for Inhalation

    Drug: AP01

  • Experimental
    AP01 Low Dose BID

    Pirfenidone Solution for Inhalation

    Drug: AP01

  • Placebo comparator
    Placebo BID

    Placebo solution for inhalation

    Other: Placebo

Interventions

  • DrugAP01

    Oral inhalation solution

    Also known as: Pirfenidone Solution

  • OtherPlacebo

    Placebo oral inhalation solution

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)

    Change from baseline in forced vital capacity (FVC) (mL)

    Time frame: Week 52

Secondary outcomes

  1. To evaluate the effect of AP01 high dose and AP01 low dose compared to placebo on disease progression (defined as absolute FVC percent predicted decline of ≥10% prior to Week 52)

    Time to disease progression

    Time frame: 52 weeks

  2. To evaluate the effect of AP01 high dose, AP01 low dose compared to placebo on quality of life (QoL)

    Absolute change from Baseline in QoL measurements as assessed by Living with Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) total score. The L-PF is a 44-item questionnaire to assess how impacted a participant is by disease symptoms on a scale from 0 (Not at all) to 4 (Extremely). The higher the summary score, the greater the impairment.

    Time frame: 52 weeks

  3. To evaluate the change from baseline in quantitative lung fibrosis score.

    Change in lung fibrosis score.

    Time frame: 52 weeks

Other outcomes

  1. To evaluate the safety of AP01 high dose and AP01 low dose compared to placebo

    Incidents of adverse events (AEs), serious adverse events (SAEs), and treatment-emergent deaths

    Time frame: 52 weeks

07

Study locations

154 sites

Showing the first 100 of 154 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • West A, Chaudhuri N, Barczyk A, Wilsher ML, Hopkins P, Glaspole I, Corte TJ, Sterclova M, Veale A, Jassem E, Wijsenbeek MS, Grainge C, Piotrowski W, Raghu G, Shaffer ML, Nair D, Freeman L, Otto K, Montgomery AB. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023 Sep;78(9):882-889. doi: 10.1136/thorax-2022-219391. Epub 2023 Mar 22. PubMed 36948586 ↗
  • Kolb M, Corte TJ, Feldman J, Nathan SD, Reisner C, Nair D, Woodhead F, Lazarus H, Conoscenti C. Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis. BMJ Open Respir Res. 2025 Dec 25;12(1):e003059. doi: 10.1136/bmjresp-2024-003059. PubMed 41448793 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.

Of 33 phase 2 interventional studies under Pulmonary Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 25, 2024
StartActual
Apr 3, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
375 (estimated)→398 (actual)
Oct 16, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedFor subjects already on background therapy (nintedanib (or nerandomilast 18 mg twice daily [up to 30% of subjects]): Must have been on nintedanibbackground therapy for at least 6 months12 weeks prior to Screening with or without dose adjustments and/or drug interruptions during that period. For subjects who have discontinued nintedanibbackground therapy prior to Screening: Must have been off of nintedanib for a minimum of 12 weeks.
Exclusion criteria
  • EditedCurrent treatment with oral pirfenidone or nerandomilast 9 mg twice daily dose or treatment with oral pirfenidone within 3 months prior to Screening.
  • EditedSignificant clinical worsening of PPF between Screening Visit 1 and Visit 3
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Enrollment 375 (estimated)→398 (actual)
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedFor subjects already on background therapy (nintedanib (or nerandomilast 18 mg twice daily [up to 30% of subjects]): Must have been on nintedanibbackground therapy for at least 6 months12 weeks prior to Screening with or without dose adjustments and/or drug interruptions during that period. For subjects who have discontinued nintedanibbackground therapy prior to Screening: Must have been off of nintedanib for a minimum of 12 weeks.
    Exclusion criteria
    • EditedCurrent treatment with oral pirfenidone or nerandomilast 9 mg twice daily dose or treatment with oral pirfenidone within 3 months prior to Screening.
    • EditedSignificant clinical worsening of PPF between Screening Visit 1 and Visit 3

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06329401
Lead sponsor
Avalyn Pharma Inc.
Collaborators
DevPro Biopharma
Responsible party
Sponsor
First posted
Mar 25, 2024
Start date
Apr 3, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Avalyn Pharma, Inc.
study director · Avalyn Pharma Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion